Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk.MethodsThe database of Taiwan’s National Health Insura...
Main Author: | Chin-Hsiao Tseng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.637392/full |
Similar Items
-
Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng, et al.
Published: (2021-02-01) -
Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis
by: Chin-Hsiao Tseng
Published: (2018-09-01) -
Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01) -
Metformin Use and Leukemia Risk in Patients With Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng, et al.
Published: (2020-10-01) -
Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)